AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+8.05%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.09B
AUM Growth
+$2.09B
(+4.3%)
Cap. Flow
+$237M
Cap. Flow
% of AUM
11.31%
Top 10 Holdings %
Top 10 Hldgs %
57.89%
Holding
113
New
16
Increased
20
Reduced
14
Closed
6
Top Buys
| 1 |
NVIDIA
NVDA
|
$75.4M |
| 2 |
Gossamer Bio
GOSS
|
$36M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$27.9M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
$21.7M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$20M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$12.2M |
| 2 |
BLUE
bluebird bio
BLUE
|
$11.8M |
| 3 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
$10M |
| 4 |
AnaptysBio
ANAB
|
$9.57M |
| 5 |
argenx
ARGX
|
$8.74M |
Sector Composition
| 1 | Healthcare | 74.84% |
| 2 | Consumer Discretionary | 19.28% |
| 3 | Technology | 3.6% |
| 4 | Real Estate | 0.42% |
| 5 | Communication Services | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lexicon Pharmaceuticals
LXRX
$400M
| $335M | 13.68% | 60,240,864 | – | – |
|
|
WW
2
DELISTED
WW International
WW
| $299M | 12.19% | 14,818,300 | – | – |
|
3
Moderna
MRNA
$9.37B
| $102M | 4.16% | 5,006,298 -250,000 | -5% | -$5.09M |
|
|
ONC
4
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $79.2M | 3.23% | 600,000 | – | – |
|
|
XLRN
5
DELISTED
Acceleron Pharma Inc.
XLRN
| $76.8M | 3.14% | 1,650,000 +600,000 | +57% | +$27.9M |
|
|
6
NVIDIA
NVDA
$4.24T
| $75.4M | 3.08% | +420,000 | New | +$75.4M |
|
7
Alibaba
BABA
$322B
| $75.2M | 3.07% | 412,000 | – | – |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $68M | 2.78% | 850,000 +250,000 | +42% | +$20M |
|
|
RUBY
9
DELISTED
Rubius Therapeutics, Inc
RUBY
| $52.7M | 2.15% | 2,908,791 | – | – |
|
|
ARRY
10
DELISTED
Array Biopharma Inc
ARRY
| $48.8M | 1.99% | 2,000,000 -500,000 | -20% | -$12.2M |
|
11
Atara Biotherapeutics
ATRA
$84.6M
| $45.7M | 1.87% | 1,150,000 +150,000 | +15% | +$5.96M |
|
12
Scholar Rock
SRRK
$3.14B
| $44.1M | 1.8% | 2,346,040 +50,000 | +2% | +$939K |
|
13
Alnylam Pharmaceuticals
ALNY
$58.5B
| $42.1M | 1.72% | 450,000 -50,000 | -10% | -$4.67M |
|
|
14
Gossamer Bio
GOSS
$562M
| $36M | 1.47% | +1,658,968 | New | +$36M |
|
15
Amicus Therapeutics
FOLD
$2.34B
| $35.4M | 1.44% | 2,600,000 -400,000 | -13% | -$5.44M |
|
16
Fate Therapeutics
FATE
$120M
| $31.6M | 1.29% | 1,800,000 -350,000 | -16% | -$6.15M |
|
17
InflaRx
IFRX
$108M
| $31.2M | 1.27% | 825,000 +325,000 | +65% | +$12.3M |
|
18
Nektar Therapeutics
NKTR
$568M
| $30.2M | 1.23% | 900,000 +100,000 | +13% | +$3.36M |
|
19
Agios Pharmaceuticals
AGIO
$2.19B
| $27M | 1.1% | 400,000 | – | – |
|
|
20
argenx
ARGX
$43.6B
| $25M | 1.02% | 200,000 -70,000 | -26% | -$8.74M |
|
21
NIO
NIO
$14.3B
| $23.5M | 0.96% | 4,600,000 -1,000,000 | -18% | -$5.1M |
|
|
EPZM
22
DELISTED
Epizyme, Inc
EPZM
| $21.7M | 0.89% | +1,750,000 | New | +$21.7M |
|
|
SAGE
23
DELISTED
Sage Therapeutics
SAGE
| $19.9M | 0.81% | 125,000 +25,000 | +25% | +$3.98M |
|
|
MDCO
24
DELISTED
Medicines Co
MDCO
| $19.6M | 0.8% | 700,000 +300,000 | +75% | +$8.39M |
|
25
ProQR Therapeutics
PRQR
$237M
| $19.4M | 0.79% | 1,400,000 | – | – |
|